Walvax Biotechnology (300142) Stock Overview
Engages in the research and development, manufacture, and distribution of vaccines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
300142 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Walvax Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.79 |
| 52 Week High | CN¥14.65 |
| 52 Week Low | CN¥9.70 |
| Beta | 0.56 |
| 1 Month Change | -4.84% |
| 3 Month Change | 2.43% |
| 1 Year Change | 0.34% |
| 3 Year Change | -69.11% |
| 5 Year Change | -70.50% |
| Change since IPO | 21.40% |
Recent News & Updates
Recent updates
Does Walvax Biotechnology (SZSE:300142) Have A Healthy Balance Sheet?
Mar 14
Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Share Price Not Quite Adding Up
Jan 18We Think Walvax Biotechnology (SZSE:300142) Can Stay On Top Of Its Debt
Nov 25Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S
Sep 24Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares
May 23There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Shareholder Returns
| 300142 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -2.8% | -2.4% |
| 1Y | 0.3% | -0.5% | 26.2% |
Return vs Industry: 300142 matched the CN Biotechs industry which returned -0.5% over the past year.
Return vs Market: 300142 underperformed the CN Market which returned 26.2% over the past year.
Price Volatility
| 300142 volatility | |
|---|---|
| 300142 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 300142 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300142's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Wei Yao | www.walvax.com |
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Walvax Biotechnology Co., Ltd. Fundamentals Summary
| 300142 fundamental statistics | |
|---|---|
| Market cap | CN¥18.68b |
| Earnings (TTM) | CN¥49.24m |
| Revenue (TTM) | CN¥2.40b |
Is 300142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300142 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.40b |
| Cost of Revenue | CN¥786.39m |
| Gross Profit | CN¥1.61b |
| Other Expenses | CN¥1.56b |
| Earnings | CN¥49.24m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 28, 2026
| Earnings per share (EPS) | 0.031 |
| Gross Margin | 67.22% |
| Net Profit Margin | 2.05% |
| Debt/Equity Ratio | 2.3% |
How did 300142 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 15:37 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Walvax Biotechnology Co., Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yizhang Zhu | Citic Securities Co., Ltd. |
| Wentao Li | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |